Literature DB >> 21308502

The next era of HCV antiviral therapy finally begins: part 2.

David Bobak1.   

Abstract

Year:  2010        PMID： 21308502     DOI： 10.1007/s11908-010-0086-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  5 in total

1.  A step forward in therapy for hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

Review 2.  The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.

Authors:  Ivan Gentile; Maria Aurora Carleo; Federico Borgia; Giuseppe Castaldo; Guglielmo Borgia
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

Review 3.  Telaprevir: hope on the horizon, getting closer.

Authors:  Ilan S Weisberg; Ira M Jacobson
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

4.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

5.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors:  Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.